When is CNTB's latest earnings report released?
The most recent financial report for Connect biopharma holdings limited (CNTB) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CNTB's short-term business performance and financial health. For the latest updates on CNTB's earnings releases, visit this page regularly.
What is the operating profit of CNTB?
According to the latest financial report, Connect biopharma holdings limited (CNTB) reported an Operating Profit of -13.42M with an Operating Margin of -27,966.67% this period, representing a decline of 283.69% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is CNTB's revenue growth?
In the latest financial report, Connect biopharma holdings limited (CNTB) announced revenue of 48K, with a Year-Over-Year growth rate of -99.8%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does CNTB have?
As of the end of the reporting period, Connect biopharma holdings limited (CNTB) had total debt of 870K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does CNTB have?
At the end of the period, Connect biopharma holdings limited (CNTB) held Total Cash and Cash Equivalents of 40.63M, accounting for 0.49 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does CNTB go with three margins increasing?
In the latest report, Connect biopharma holdings limited (CNTB) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -27,966.67%%, and net margin of -26,872.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CNTB's profit trajectory and future growth potential.
Is CNTB's EPS continuing to grow?
According to the past four quarterly reports, Connect biopharma holdings limited (CNTB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.23. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CNTB?
Connect biopharma holdings limited (CNTB)'s Free Cash Flow (FCF) for the period is -12.89M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 53.32% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
